By Tess Stynes 
 

Pfizer Inc. (PFE) said its experimental anti-cholesterol treatment significantly reduced LDL-C cholesterol across several dosing levels in a Phase 2b study of patients at high risk for cardiovascular events.

Bococizumab--also known as RN316--is part of a class of treatments called PCSK9 inhibitors, which are being developed by several major drug companies. Analysts and investors have watched development of the drugs closely because of their potential to treat millions of patients whose high cholesterol isn't well controlled with statins.

The study included statin-treated patients with high cholesterol who received doses of either bococizumab twice or once monthly subcutaneous administration or placebo. The study met its primary endpoint across all doses, Pfizer said.

Elevated LDL-C is recognized as a major risk factor for cardiovascular disease.

Write to Tess Stynes at tess.stynes@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Pfizer Charts.